Sutro Biopharma (STRO) Retained Earnings (2017 - 2026)

Sutro Biopharma has reported Retained Earnings for 9 years, with the latest figure at -$978.0 million in Q4 2025.

• Quarterly Retained Earnings fell 24.29% year-over-year to -$978.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$978.0 million (down 24.29% YoY) and the FY2025 annual result came in at -$978.0 million, down 24.29% from the prior year.
• Retained Earnings retreated to -$978.0 million in Q4 2025 per STRO's latest filing, from -$931.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at $106000.0 in Q3 2024 and troughed at -$978.0 million in Q4 2025.
• A 5-year average of -$349.3 million and a median of -$261.3 million in 2021 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 1414.29% in 2024, then sank 878583.96% in 2025.
• Over 5 years, Retained Earnings stood at -$314000.0 in 2021, then tumbled by 144044.9% to -$452.6 million in 2022, then decreased by 23.59% to -$559.4 million in 2023, then slumped by 40.66% to -$786.9 million in 2024, then dropped by 24.29% to -$978.0 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$978.0 million, -$931.2 million, and -$874.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.